ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Study: Rencarex Treatment Efficacy Increases With CAIX Antigen Density in Tumor Tissue

March 29, 2013

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

May 22, 1981

Senate Committee Proposes $301 Million Increase For NIH

September 22, 1995

Cancer Letter Editor Wine Reporting Awards

June 11, 1999

Murray Copeland Display Dedicated

March 18, 1983

Three Cancer Centers Test Targeted Therapy For Resistant Acute Myelogenous Leukemia

July 26, 2002